20
29th CINP World
Congress 2014
Preliminary Scientific Programme |
Thursday, 26 June 2014
S-31
e
Symposium
09:00 – 11:00
Topic: Depression (A)
Track: Translational
Polypharmacy in psychotic and affective disorders: Co-
medication with antipsychotic and antidepressant drugs
Chair:
Hans-Jürgen Möller, Germany
Co-chair: Barbara J. Sahakian, United Kingdom
Treatment of negative vs. other symptoms in schizophrenia
Hans-Jürgen Möller, Germany
Concomitant antidepressant and antipsychotic medication
in schizophrenia and depression – mechanisms of action
Torgny Svensson, Sweden
The role of atypical antipsychotics as add-on medication
in major depression
Siegfried Kasper, Austria
Current evidence for treatment of cognitive dysfunction
in depression
Barbara J. Sahakian, United Kingdom
S-32
e
Symposium
09:00 – 11:00
Topic: Schizophrenia (A)
Track: Basic
New insights into the role of NMDA receptors in cognition
and psychosis
Chair:
Andrew Holmes, USA
Co-chair: Stan Floresco, Canada
NMDA-GluN2B receptors govern corticostriatal learning
and cognitive flexibility
Andrew Holmes, USA
NMDA receptor-associated proteins, cognition, and neu-
ropsychiatric disorders – translation between mouse and
human
Tim Bussey, United Kingdom
NMDA receptors and behavioural flexibility: For when
things aren’t the way they used 2B
Stan Floresco, Canada
NMDA receptors mediate the persistent firing of dorso-
lateral prefrontal cortical circuits underlying mental rep-
resentation
Amy Arnsten, USA
S-33
e
Symposium
09:00 – 11:00
Topic: Biomarkers (including pharmacogenomics and
brain imaging) for diagnosis and treatment response (C)
Track: Translational
Converting biological findings into routine clinical tests –
Psychiatry’s next big challenge
Chair:
Shitij Kapur, United Kingdom
Co-chair: Roy Perlis, USA
Converting biological psychiatry into clinical tests – why
has it been so hard and what to do about it
Shitij Kapur, United Kingdom
Clinical relevance – what does it mean when developing
clinical tests
Rudolf Uher, Canada
From pharmacogenetics to clinical tests
Roy Perlis, USA
Pharmacogenetic tests for psychotropics – a journey from
bench to bedside
Tony Altar, USA
S-34
e
Symposium
09:00 – 11:00
Novel therapeutics
Chair:
Elias Eriksson, Sweden
S-35
e
Symposium
09:00 – 11:00
Topic: Attention deficit disorders (D)
Track: Translational
Adult ADHD and obesity: Neurotransmitter imaging and
pharmacotherapies targeting impulsivity
Chair:
Ulrich Muller, United Kingdom
Co-chair: Catharine Winstanley, Canada
Preclinical models of impulsivity: Pharmacological and
dietary manipulations
Catharine Winstanley, Canada
Imaging of the dopaminergic system in ADHD, binge
eating and obesity
Gene-Jack Wang, USA
Imaging of the noradrenergic system in adults with
obesity and ADHD
Swen Hesse, Germany
Pharmacological treatment of ADHD in adults: Implica-
tions for binge eating and obesity
Ulrich Muller, United Kingdom
